LUVANTAS

Serial Number 97715850
Registration 7477829
700

Registration Progress

Application Filed
Dec 13, 2022
Under Examination
Jul 25, 2023
Approved for Publication
May 30, 2023
Published for Opposition
Jun 4, 2024
Registered
Aug 20, 2024

Trademark Image

LUVANTAS

Basic Information

Serial Number
97715850
Registration Number
7477829
Filing Date
December 13, 2022
Registration Date
August 20, 2024
Published for Opposition
June 4, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 20, 2024
Registration
Registered
Classes
005

Rights Holder

Medytox Inc.

03
Address
78, Gangni 1-gil, Ochang-eup
Cheongwon-gu, Cheongju-si
Chungcheongbuk-do 28126
KR

Ownership History

Medytox Inc.

Original Applicant
03
Chungcheongbuk-do KR

Medytox Inc.

Owner at Publication
03
Chungcheongbuk-do KR

Medytox Inc.

Original Registrant
03
Chungcheongbuk-do KR

Legal Representation

Attorney
Mark J. Liss

USPTO Deadlines

Next Deadline
1708 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240820)
Due Date
August 20, 2030
Grace Period Ends
February 20, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description Documents
Aug 20, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 20, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 4, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 4, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 29, 2024 ATRV O ATTORNEY REVIEW COMPLETED Loading...
May 29, 2024 ATRV O ATTORNEY REVIEW COMPLETED Loading...
May 15, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 2, 2024 OTHE I CASE RETURNED TO EXAMINATION Loading...
May 2, 2024 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Apr 25, 2024 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Apr 25, 2024 PCBG O PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Loading...
Apr 23, 2024 APET A ASSIGNED TO PETITION STAFF Loading...
Mar 29, 2024 TPAD I TEAS PETITION TO AMEND BASIS RECEIVED Loading...
Jan 23, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 19, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 19, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 19, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 25, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 30, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 30, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 10, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 26, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 21, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 21, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 21, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 5, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 5, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 5, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 28, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 16, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 16, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Implantable medicines for treating neurological disorders and muscle dystonia; implantable antiaging medicines, namely, botulinum toxin for medical use for treatment of facial wrinkles; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain

Additional Information

Translation
The wording "LUVANTAS" has no meaning in a foreign language

Classification

International Classes
005